Skip to main content

Advertisement

SpringerLink
Log in

Clinical efficacy and safety of using calcipotriol–betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The main objective is to evaluate clinical efficacy and safety of using calcipotriol–betamethasone compounding agent for psoriasis treatment through a systematic review and meta-analysis. We searched MEDLINE, Embase, The Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and WanFang Data from inception till July 31, 2020. Efficacy was evaluated based on primary outcome indicators including skin lesion improvement and overall adverse reaction rate. Secondary outcome indicators included degree of life quality improvement, clinical effectiveness rate, and specific adverse reaction rates. RevMan5.3 was used to perform the meta-analysis. 22 studies finally met our inclusion criteria for the meta-analysis. The results indicated that for short-term treatment, a sequential therapy that uses calcipotriol betamethasone compounding agent and calcipotriol improves PASI score (MD = −0.94, 95% CI − 1.38 ~ − 0.49, P < 0.0001, I2 = 49%), comparing with using only calcipotriol. From a drug safety perspective, the difference in overall adverse reaction rate is not significant between the calcipotriol group and the sequential treatment group (RR = 0.50, 95% CI 0.22 ~ 1.14, P = 0.10, I2 = 33%). Calcipotriol betamethasone compounding agent may be more effective in plaque psoriasis treatment compared to use only calcipotriol, with no significant difference in adverse reaction rate between the two groups. Although the data were collected from 13 comparison groups, each group may not have sufficient data for a thorough and comprehensive analysis. Further research may be necessary for a more detailed evaluation of effectiveness of using calcipotriol betamethasone compounding agent for plaque psoriasis treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ et al (2016) Psoriasis. Nat Rev Dis Primers 2:16082

  2. Drvar DL, Vlahinić T, Maleš Ž, Turčić P, Čeović R (2019) A modern approach to the treatment of plaque psoriasis. Acta Pharm 69:511–523

    Article  CAS  PubMed  Google Scholar 

  3. World Health Organization (2016) Global report on psoriasis. World Health Organization. https://apps.who.int/iris/handle/10665/204417

  4. Zhou J, Yi X, Li Y, Ding Y (2018) Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis. Lasers Med Sci 33:1979–1982

    Article  PubMed  Google Scholar 

  5. Stein Gold LF (2016) Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg 35:S36–S44 (quiz S45)

    Article  PubMed  Google Scholar 

  6. Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, Chu AC (2006) Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert Opin Pharmacother 7:597–606

    Article  CAS  PubMed  Google Scholar 

  7. Wang RC, Levine B (2011) Calcipotriol induces autophagy in HeLa cells and keratinocytes. J Invest Dermatol 131:990–993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Guzzo C, Lazarus G, Goffe BS, Katz HI, Lowe NJ, Pincus SH (1996) Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 34:429–433

    Article  CAS  PubMed  Google Scholar 

  9. Rizova E, Corroller M (2001) Topical calcitriol–studies on local tolerance and systemic safety. Br J Dermatol 144(Suppl 58):3–10

    CAS  PubMed  Google Scholar 

  10. Sips AJ, Netelenbos JC, Barto R, Verburgh CA, Nieboer C, van der Vijgh WJ (1994) Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. J Am Acad Dermatol 30:966–969

    Article  CAS  PubMed  Google Scholar 

  11. Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L et al (2012) Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 26(Suppl 3):52–60

    Article  CAS  PubMed  Google Scholar 

  12. van de Kerkhof PC, Vissers WH (2003) The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16:69–83

    Article  PubMed  CAS  Google Scholar 

  13. Koo J, Liao W (2000) Update on psoriasis therapy: a perspective from the USA. Keio J Med 49:20–25

    Article  CAS  PubMed  Google Scholar 

  14. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J et al (2012) Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol 2012:561018

  15. Piérard GE, Piérard-Franchimont C, Ben Mosbah T, Arrese Estrada J (1989) Adverse effects of topical corticosteroids. Acta Derm Venereol Suppl (Stockh) 151:26–30 (discussion 47-52)

    Google Scholar 

  16. Simonsen L, Høy G, Didriksen E, Persson J, Melchior N, Hansen J (2004) Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm 30:1095–1102

    Article  CAS  PubMed  Google Scholar 

  17. Committeeon Psoriasis,Chinese Society of Dermatology (2019) Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition). Chin J Dermatol 52(10):667–710

  18. Cpga C (2016) 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med Surg 20:375–431

    Article  Google Scholar 

  19. Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S et al (2018) Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol 45:805–811

    Article  PubMed  PubMed Central  Google Scholar 

  20. Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW (2012) Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol 148:511–522

    Article  CAS  PubMed  Google Scholar 

  21. van de Kerkhof PC, Wasel N, Kragballe K, Cambazard F, Murray S (2005) A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 210:294–299

    Article  PubMed  CAS  Google Scholar 

  22. Anstey AV, Kragballe K (2006) Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 45:970–975

    Article  CAS  PubMed  Google Scholar 

  23. Bottomley JM, Taylor RS, Ryttov J (2011) The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin 27:251–268

    Article  CAS  PubMed  Google Scholar 

  24. van de Kerkhof P, de Peuter R, Ryttov J, Jansen JP (2011) Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin 27:225–238

    Article  PubMed  CAS  Google Scholar 

  25. Girolomoni G, Vena GA, Ayala F, Cannavò SP, De Pità O, Chimenti S et al (2012) Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol 147:609–624

    CAS  PubMed  Google Scholar 

  26. Mason A, Mason J, Cork M, Hancock H, Dooley G (2013) Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol 69:799–807

    Article  CAS  PubMed  Google Scholar 

  27. Abdelmaksood R, Hashad D (2013) The impact of topical calcipotriol and betamethasone on human beta-defensin 2 expression and serum level in psoriatic patients. Clin Lab 59:277–282

    CAS  PubMed  Google Scholar 

  28. Kubin ME, Kokkonen N, Palatsi R, Hägg PM, Väyrynen JP, Glumoff V et al (2017) Clinical efficiency of topical calcipotriol/betamethasone treatment in psoriasis relies on suppression of the inflammatory TNFα - IL-23 - IL-17 Axis. Acta Derm Venereol 97:449–455

    Article  CAS  PubMed  Google Scholar 

  29. Khandpur S, Sahni K (2014) An open label prospective randomized trial to compare the efficacy of coal tar-salicylic Acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol 59:579–583

    Article  PubMed  PubMed Central  Google Scholar 

  30. Vena GA, Galluccio A, Pezza M, Vestita M, Cassano N (2012) Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study. J Dermatolog Treat 23:255–260

    Article  CAS  PubMed  Google Scholar 

  31. Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K et al (2011) Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 25:1012–1020

    Article  CAS  PubMed  Google Scholar 

  32. Bin Y, Lian W (2019) Clinical effect of calcipotriol betamethasone cream and calcipotriol ointment in sequential treatment of plaque psoriasis. J Clin Ration Drug Use 12:107–108

    Google Scholar 

  33. Qin LH, Yan X (2018) Therapeutic efficacy of 308 nm excimer light combined with calcipotriol betamethasone ointment in plaque psoriasis. J Changzhi Med Coll 32:452–454

    Google Scholar 

  34. Wang Q, Xie B, Sun XD, Wang H, Yun BL, Li W et al (2018) Clinical efficacy of calcipotriol betamethasone ointment for scalp plaque psoriasis. J Clin Dermatol 47:677–678

    CAS  Google Scholar 

  35. Yao YF, Sun ZJ, Yang F, Fang SN (2018) Therapeutic effects of 308 nm high-energy excimer light plus calcitriol betamethasone ointment on chronic plaque psoriasis. Clin J Chin Med 10:58–60

    Google Scholar 

  36. Xu H, Fei YW, Gu JY, Gong Y, Li XL, Liu ZY et al (2017) Clinical efficacy of calcipotriol betamethasone ointment for psoriasis vulgaris. J Clin Dermatol 46:800–803

    Google Scholar 

  37. Ge WT, Chen Y, Guo BC (2014) Therapeutic effect of calcipotriol betamethasone ointment on plaque psoriasis. China J Lepr Skin Dis 30:192

    Google Scholar 

  38. Wang B, Liu WB, Sun LW, Yang H, Xiang Y (2017) Sequential use of calcipotriol betamethasone cream and calcipotriol ointment for psoriasis. J Clin Dermatol 46:353–355

    Google Scholar 

  39. Fan X, Li L, Yang YL, Zhang J (2019) Clinical effect of sequential therapy with Dovobet and Daivonex in that treatment of plaque psoriasis vulgaris. J Hubei Univ Sci Technol (Med Sci) 33:413–414

  40. Yang W (2018) Clinical evaluation of calcipotriol betamethasone ointment in the treatment of plaque psoriasis. J Clin Med Lit 5:74–75

    Google Scholar 

  41. Zhen Z (2016) Clinical effect of calcipotriol betamethasone ointment in treatment with plaque psoriasis. Women’s Health Res 2:3–4

    Google Scholar 

  42. Zhang J, Jiang GP, Yang MH, Yang YL, Yan-li C (2014) Assessment of effect of calcipotriol betamethasone ointment on plaque type psoriasis. China J Lepr Skin Dis 30:41–42

    Google Scholar 

  43. Sun YX, Fang F, Cui BN, Huang Q, Jiang GX, Dai YY et al (2013) Caicipotriol betamethasone ointment combined with narrow band-ultraviolet B in the treatment of plaque-type psoriasis: a randomized controlled study. Chin J Dermatol 46:831–833

    Google Scholar 

  44. Ding XY, Zhao ZG, Guo XL, Lin BW, Li HJ (2012) Therapeutic effect of calcipotriol betamethasone ointment on plaque psoriasis. Chin J Lepr Dermatol 28:439–440

    Google Scholar 

  45. Wang X, Dai YY (2019) Clinical study of calcipotriol betamethasone ointment in the treatment of scalp plaque psoriasis. China Health Care Nutr 29:279

    Google Scholar 

  46. Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N et al (2021) Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial. J Eur Acad Dermatol Venereol 35:143–149

    Article  PubMed  CAS  Google Scholar 

  47. Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P et al (2007) Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 18:361–365

    Article  CAS  PubMed  Google Scholar 

  48. Jianfeng X (2020) Clinical effect of narrow-band ultraviolet B combined with calcipotriol betamethasone in the treatment of senile patients with moderate and severe psoriasis. Clin Res Pract 5:115–117

    Google Scholar 

  49. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH (2013) Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol 168:954–967

    Article  CAS  PubMed  Google Scholar 

  50. Ashcroft DM, Po AL, Williams HC, Griffiths CE (2000) Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 320:963–967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Tianjin municipal health and Health Committee (ZC20114).

Author information

Authors and Affiliations

  1. Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

    Junrong Ren & Hongmei Wang

  2. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    Qi Zhu, Siyao Wang, Xiaolong Li, Zhen Sun, Nan Li, Jian Feng & Haining Ding

  3. Systematic Review Solutions Ltd, The Ingenuity Centre, Triumph Road, Nottingham, NG7 2TU, UK

    Sitong Dong

Authors
  1. Junrong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Siyao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaolong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhen Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Haining Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sitong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hongmei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by JR, QZ, SW, XL, ZS, NL, JF, HD and SD. The first draft of the manuscript was written by QZ, SW, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hongmei Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics approval

This study is a systematic review and meta-analysis and does not involve any ethical issues.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 387 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ren, J., Zhu, Q., Wang, S. et al. Clinical efficacy and safety of using calcipotriol–betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis. Arch Dermatol Res 314, 633–641 (2022). https://doi.org/10.1007/s00403-021-02272-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-021-02272-5

Keywords

Search

Navigation